Narlumosbart

Phase 3Small molecule

SShanghai JMT-Bio Inc.

Narlumosbart is one of 91 small molecule programs targeting Giant Cell Tumor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Giant Cell TumorNot yet recruiting

Multiple MyelomaNot yet recruiting

NSCLCRecruiting

Giant Cell TumorPhase 3

Not yet recruiting

Multiple MyelomaPhase 3

Not yet recruiting

NSCLCPhase 2

Recruiting

Competition

Competitive Landscape

259 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Belamaf

GSK

Phase 3

39 2

Empliciti

Bristol-Myers Squibb

Phase 3

43 3

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 4

Biaxin

AbbVie

Phase 3

14 5

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

28 6

Vepesid

AAvyxa

Phase 3

17 7

Mozobil

GGenzyme, a Sanofi Company

Phase 3

15 8

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

11 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 10

Etentamig

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

Multiple Myeloma

NCT06314698

Q3 2028

Phase 3Not yet recruiting

Giant Cell Tumor

NCT05813665

Q4 2028

Phase 2Recruiting

NSCLC

NCT06738160

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Not yet recruiting·RRenJi Hospital·Phase 3·NCT06314698·478 enrolled

Giant Cell Tumor1 trial

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT05813665·146 enrolled

NSCLC1 trial

Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy Followed by First-line Chemotherapy Combined With Immunotherapy in Advanced Driver Gene-negative Non-small Cell Lung Cancer Patients With Bone Metastases: A Phase II, Single-arm, Single-center Clinical Trial Protocol

Recruiting·FFudan University·Phase 2·NCT06738160·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Narlumosbart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Narlumosbart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Narlumosbart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai JMT-Bio Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShanghai JMT-Bio Inc.

Narlumosbart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2028

Q4 2028

Trials by Indication[1]

Multiple Myeloma1 trial

Giant Cell Tumor1 trial

NSCLC1 trial

References

Drug Info

Quick Facts

Related News